Shree Ganesh Rem Q1 FY27 Results (NSE: SGRL)

· Analysis by Alpha Inflection

Signal: Revenue declined

The read

The trajectory has deteriorated for a fourth consecutive quarter of YoY margin contraction in the prior-results series: the filing's operating EBITDA margin fell to 23.3% from 29.6% in Q1FY26 and 34.3% in Q4FY26, while revenue fell 41.8% YoY; recovery is explicitly pushed to H2FY27, making European order normalisation and CRAMS conversion the key thesis inflection points.

Shree Ganesh Rem Q1 FY27 key financials
MetricValueYoYQoQ
Revenue₹14.36 Cr-41.8%-57%
EBIT₹1.85 Cr-66.6%
Net profit₹1.12 Cr-67.5%
EPS₹0.87-67.5%
EBIT margin29.9%

P&L walk

Revenue declined to ₹14.36 crore (-41.8% YoY, -57% QoQ) as European customers deferred orders; XBRL EBITDA was ₹4.29 crore, EBIT ₹1.85 crore and PAT ₹1.12 crore, while other income of ₹0.94 crore represented 61.4% of PBT.

Segments

The filing does not provide a formal segment-results table, but pharma intermediates contributed ₹11.49 crore versus ₹2.88 crore from specialty chemicals; exports were ₹8.64 crore versus ₹5.72 crore domestic sales, with the disclosed weakness concentrated in European demand.

Key positives

Key concerns

Earnings quality: includes non-operating other income

View original filing

Research and educational content only. Not investment advice.